Key Highlights
- 23.46% is the one-week gain in Portillo's (NASDAQ:PTLO), the largest of four overbought stocks, to USD 4.82 on October 16, 2026, per published market data. The 14-day RSI is 76.3, and no company-specific catalyst was identified in the filings and releases reviewed.
- 11.23% is the one-week gain in Wingstop (NASDAQ:WING) to USD 133.83, with an RSI of 71.0, while domestic same-store sales fell 7.5% in the quarter ended June 27, 2026, per the 8-K dated July 29. Results are due October 28, 2026.
- 10.69% is the one-week gain in Nu Skin (NYSE:NUS) to USD 5.28, with an RSI of 71.1 and a USD 257 million market capitalization. Second quarter revenue fell 17.1% to USD 320.1 million, per the August 10, 2026 release.
- 10.41% is the one-week gain in Privia Health (NASDAQ:PRVA) to USD 22.43, with an RSI of 70.6. Second quarter revenue rose 21.4% to USD 632.6 million, per the August 6, 2026 release, and the next report is November 5, 2026.
Portillo's (NASDAQ:PTLO)
The largest weekly gain on the list added USD 69.5 million of market capitalization (own arithmetic on the USD 366 million figure), and the company filed nothing that changes its outlook. The implied price a week ago was USD 3.90, own arithmetic on two published numbers, and the shares now sit above the 50-day average of USD 4.24 and the 200-day average of USD 4.58. UBS cut its target to USD 4.50 on October 9, and Stephens kept Equal Weight with USD 5.00 on October 15. Net debt of USD 316.7 million is 3.4 times the USD 94 million midpoint of 2026 adjusted EBITDA guidance, own arithmetic. Second quarter same-restaurant sales fell 1.2% and transactions fell 3.4%. What separates PTLO: the only gain above 20% and the only one with a recent analyst target cut, from UBS. So what: the move reflects trading flows, and the November 5, 2026 report is the first test, when same-restaurant sales against the 1.2% decline and restaurant-level margin against the 19.5% to 20.5% target are the lines to watch.
Wingstop (NASDAQ:WING)
The market is pricing a recovery that the latest filing does not yet show. The 11.23% gain added USD 368.5 million of market capitalization, own arithmetic on USD 3.65 billion, the largest dollar amount of the four, though it ranks second on percentage. Domestic same-store sales fell 7.5% in the second quarter and are guided down 4% to 6% for 2026. Adjusted EPS of USD 1.18 beat the USD 1.02 consensus, while revenue of USD 185.6 million trailed the USD 190.25 million consensus. Growth came from units: 102 net new openings lifted the system to 3,255 restaurants. Net debt was USD 1.08 billion, own arithmetic, and published market data show a median analyst target of USD 234.5, so the quote is 42.9% below it. What separates WING: a franchisor adding toll booths that each collect less, with the earliest report date. So what: October 28 must show same-store sales stabilizing. Net interest expense is guided at USD 43 million for 2026, against a quarterly dividend cost of USD 9.0 million, so leverage limits flexibility if comparable sales weaken.
Nu Skin (NYSE:NUS)
A gain of 10.69% normally needs a trigger, and none was found. The implied price a week ago was USD 4.77, own arithmetic, so the week added only USD 24.8 million of market capitalization, own arithmetic on USD 257 million. Management expects USD 5 million of cash transition costs in the third quarter. The headline second quarter loss of USD 249.8 million is mostly accounting: USD 78.9 million of impairment and a USD 167.5 million non-cash valuation allowance. Adjusted EPS guidance of USD 0.70 to USD 0.90 gives 6.6 times the midpoint, and net debt is USD 24.1 million. Customers fell 14% to 660,037. What separates NUS: the smallest company, the lowest valuation and the weakest revenue, down 17.1%. So what: a depressed base magnifies percentage moves, and the estimated November 5 report decides if declines narrow toward the 7% end of third quarter revenue guidance of USD 310 million to USD 340 million. The dividend of USD 0.06 a quarter yields 4.5%, own arithmetic.
Privia Health (NASDAQ:PRVA)
The stake is whether a thin-margin growth story deserves a rising multiple. The 10.41% gain added USD 269.7 million of market capitalization, own arithmetic on USD 2.86 billion. Privia manages value-based contracts and earns revenue when patient populations cost less than benchmarks. Adjusted EBITDA rose 29.1% to USD 37.4 million, while GAAP net income of USD 9.0 million is a 1.4% margin, own arithmetic. Attributed lives rose 19.2% to 1,647,000, and 2026 lives guidance was raised to 1,625,000 to 1,650,000. Against the USD 150 million midpoint of adjusted EBITDA guidance, the market capitalization is 19.1 times, ignoring net cash, which is not disclosed in the releases reviewed. What separates PRVA: the strongest fundamentals and the smallest weekly gain. So what: the gain reprices a guided second half, and results arrive before the open on November 5, 2026, with a release by 7:00 a.m. ET and a call at 8:00 a.m. ET. Guidance sits at the mid to high end of its ranges, which leaves limited room for disappointment.
Where Things Stand
Portillo's (NASDAQ:PTLO) posted the largest one-week gain at 23.46%, ahead of Wingstop at 11.23%, Nu Skin at 10.69% and Privia Health at 10.41%, per published market data on October 16, 2026. The spread between first and last is 13.05 percentage points (own arithmetic). The ranking is inverse to fundamental support. Privia Health (NASDAQ:PRVA) has 21.4% revenue growth. Nu Skin (NYSE:NUS) has a 17.1% decline. No company-specific catalyst was identified for any of the four, so each move is a trading outcome whose durability depends on the next report. The first dated test is Wingstop (NASDAQ:WING) on October 28, 2026, then Portillo's and Privia on November 5.






Please wait processing your request...